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Glioblastoma multiforme (GBM) is the most common
brain tumor, with a poor prognosis of less than 14
months after initial diagnosis. Gene amplification and
mutation of epidermal growth factor receptor (EGFR)
are frequently observed in primary GBM. The most
common variant of EGFR, known as EGFRvIII, is
expressed in approximately 30% of GBM patients, but is
absent on normal cells, making it a desirable target for
cancer immunotherapy. In addition to the surge of
adoptive cell immunotherapies for the treatment of
advanced cancers, chimeric antigen receptors (CARs)
have come to the forefront as a promising therapeutic
strategy. We have engineered genetically modified
T cells to express CARs that specifically target tumor
cells expressing EGFRvIII and/or amplified EGFR for
the treatment of malignant gliomas.
Our studies have focused on optimizing the EGFRvIII-
CAR structural design, including the antigen-targeting
domain (scFv), extracellular non-signaling linker, and
intracellular co-stimulatory signaling domains, to
improve overall CAR T cell specificity and efficacy.
Thus, we have compared five different scFvs for target-
ing EGFRvIII, and four different linkers with varying
lengths. CAR activity was evaluated using a variety of in
vitro functional assays, including CD107a degranulation,
IFN-g production, PD-1 induction, T cell proliferation
and tumor killing assays. Using these assays, we have
defined CARs capable of mediating highly-specific acti-
vation and killing of target tumor cells expressing
EGFRvIII and/or amplified EGFR, with minimal target-
ing of endogenous EGFR-expressing cells. We further
validated our EGFRvIII-specific CAR T cells using pre-
clinical human xenograft models of GBM. Our in vivo
tumor studies show dose-dependent killing by locally
administered EGFRvIII-CAR T cells against subcuta-
neous tumors expressing EGFRvIII. Combined, these
studies demonstrate potent anti-tumor activity of EGFR-
vIII-specific CAR T cells.
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